Authors
Latest:
Dr. Jeyarajah on Aggressive Treatment while Preserving Quality of Life in CRCRohan Jeyarajah, MD, discusses aggressive treatment while preserving quality of life in patients with colorectal cancer.
Latest:
Data Quality Issues Plague the US Health Care SystemOleg Bess, MD, explains why data quality is essential to improving the United States health care system.
Latest:
Dr Stein on Key Considerations When Selecting an Immunotherapy Approach in HCCStacey Stein, MD, discusses key considerations when selecting a first-line treatment approach for higher-risk patients with hepatocellular carcinoma, and in what scenarios the combination of atezolizumab and bevacizumab is a viable approach in this population.
Latest:
Dr Sumrall on the Clinical Efficacy of ONC201 in H3K27M -Mutant Diffuse Midline GliomasAshley Sumrall, MD, FACP, medical oncologist, section chief, Neuro-Oncology, clinical assistant professor, medicine, Atrium Health, Levine Cancer Institute, discusses the clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas.
Latest:
Dr. Jain on Ongoing Research Efforts in MCLPreetesh Jain, MD, PhD, discusses ongoing research efforts in mantle cell lymphoma.
Latest:
Dr Doroshow on RET Inhibitors in RET Fusion+ NSCLCDeborah B. Doroshow, MD, PhD, discusses the similarities and differences between the efficacy and safety profiles of pralsetinib and selpercatinib in patients with non–small cell lung cancer harboring RET fusions.
Latest:
Ongoing Clinical Trials With ADC Therapy in HR+ Metastatic Breast CancerBreast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.
Latest:
Dr Ailawadhi on Early Data for Iopofosine I 131 in Waldenström MacroglobulinemiaSikander Ailawadhi, MD, discusses early efficacy and safety data for iopofosine I 131 monotherapy in Waldenström macroglobulinemia.
Latest:
Dr. Shah on the Significance of the Approval of Sodium Thiosulfate in Pediatric Solid TumorsNilay Shah, MD, discusses the significance of the approval of sodium thiosulfate for pediatric patients with cisplatin-treated pediatric solid tumors.
Latest:
Long-Term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-Positive Thyroid CarcinomaDr. Waguespack reviews efficacy and safety data for larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Latest:
Future Directions for HCC ManagementDrs Josep Llovet, Stephen L. Chan, and Andrea Casadei Gardini discuss the future treatment landscape for HCC.
Latest:
Dr. Kato on the Characterization of BRAF Mutations in OncologyShumei Kato, MD, discusses the characterization of BRAF mutations in oncology.
Latest:
Dr. Arora on the Evolution of Treatment in Follicular LymphomaMadan L. Arora, MD, discusses the evolution of treatment in follicular lymphoma.
Latest:
Dr. Lipson on the Impact of Preoperative Nivolumab Plus Relatlimab in NSCLCEvan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).
Latest:
Dr Ignatz-Hoover on the Future of CAR T-Cell Therapy and Bispecific Antibodies in R/R MyelomaJames Ignatz-Hoover, MD, PhD, discusses the future of CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma.
Latest:
Dr Machaalani on the Incidence of ERBB2 Amplifications Across Race, Sex, and Cancer TypeMarc Machaalani, MD, discusses an investigation into the distribution of ERBB2 amplifications across sex, race, and varying cancer types.
Latest:
Dr Khalil on the Future Investigations of Immunotherapy in NSCLCMaya Khalil, MD, discusses the future investigations of immunotherapy in non–small cell lung cancer.
Latest:
Dr. Azzi on the Utilization of the Signatera ctDNA Assay in the CIRCULATE-US Trial in CRCGeorges Azzi, MD, co-director, Department of Hematology/Oncology, Prostate Cancer, Holy Cross Health, discusses the utilization of the Signatera circulating tumor DNA assay in the ongoing phase 2/3 CIRCULATE-US trial in colorectal cancer.
Latest:
Dr Buchbinder on Treatment With Nivolumab Maintenance Following irAEs in MelanomaElizabeth Buchbinder, MD, discusses the investigation of treatment with nivolumab maintenance therapy in patients with melanoma who experienced severe immune-related adverse effects associated with combination therapy with nivolumab and ipilimumab.
Latest:
Dr. Talwar on the Utility of Immunotherapy in Metastatic Urothelial CarcinomaVineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.
Latest:
Dr. Rhee on the Benefit of Zanubrutinib Vs Ibrutinib in R/R CLLJune-Wha Rhee, MD, discusses the benefit of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, as well as the incidence of cardiac disorders associated with the BTK inhibitors.
Latest:
Dr Meisel on the Impact of Endocrine Therapy–Related Toxicities on QOL in ER+/HER2– Breast CancerJane L. Meisel, MD, discusses the impact of toxicities associated with endocrine therapy on quality of life as reported by patients with metastatic breast cancer.
Latest:
Dr. Akbar on the Efficacy of Monoclonal Antibodies Across Various Trials in R/R ALLUsman Ali Akbar, MD, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia.
Latest:
Dr Shiu on the FDA Approval of Pembrolizumab Plus Chemotherapy in Advanced HER2– Gastric/GEJ AdenocarcinomaKai-Keen Shiu, MD, discusses the significance of the FDA approval of pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment in patients with locally advanced, unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Latest:
Dr Tang on Unanswered Questions About the Role of Radiation Therapy in RCCChad Tang, MD, discusses unanswered questions surrounding the role of radiation therapy in renal cell carcinoma.
Latest:
Dr. Cheah on the Investigation of BGB-11417 With or Without Zanubrutinib in CLLChan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.
Latest:
Operational Processes and ChallengesMark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.
Latest:
Patient Selection and Sequencing of NSCLC ADCsThe panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.
Latest:
Dr. Brayer on the Promise of BiTEs in Multiple MyelomaJason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.
.jpg?fit=crop&auto=format)
